分组1 - Core Laboratories reported quarterly earnings of $0.21 per share, exceeding the Zacks Consensus Estimate of $0.20 per share, but down from $0.22 per share a year ago, representing an earnings surprise of +5.00% [1] - The company achieved revenues of $138.26 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 4.52% and increasing from $129.24 million year-over-year [2] - Core Laboratories has outperformed the S&P 500 with a share price increase of about 22.5% since the beginning of the year, compared to the S&P 500's gain of 1.1% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is $0.18 on revenues of $135.66 million, and for the current fiscal year, it is $0.79 on revenues of $531.74 million [7] - The Oil and Gas - Field Services industry, to which Core Laboratories belongs, is currently ranked in the top 28% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]

Financial Performance - Fourth quarter 2025 revenue was $138.3 million, up 3% sequentially and up 7% year-over-year[2]. - Fourth quarter operating income was $15.8 million, with operating margins of over 11%, down 100 basis points sequentially and 80 basis points year-over-year[3]. - Full year 2025 revenue was $526.5 million, slightly up from 2024, with full year EPS, ex-items, of $0.75, down 14%[3]. - The Company reported Q4 2025 revenue of $138,255,000, representing a 2.8% increase from Q3 2025 and a 7.0% increase from Q4 2024[33]. - Operating income for Q4 2025 was $15,832,000, down 24.4% from Q3 2025 but up 11.7% from Q4 2024[33]. - Net income attributable to Core Laboratories Inc. for Q4 2025 was $7,082,000, a decrease of 50.3% compared to Q3 2025 and a decrease of 4.3% compared to Q4 2024[33]. - For the full year 2025, total revenue was $526,520,000, a slight increase of 0.5% from $523,848,000 in 2024[35]. - The Company’s operating income for the year ended December 31, 2025, was $56,468,000, down 3.6% from $58,556,000 in 2024[35]. - Net income for the year ended December 31, 2025, was $32,525,000, an increase from $32,153,000 in 2024, representing a growth of 1.16%[39]. - The company reported a diluted earnings per share of $0.68 for the year ended December 31, 2025, consistent with the previous year[45]. Cash Flow and Debt Management - Free cash flow for the fourth quarter was $5.1 million, with full year free cash flow totaling $26.0 million[3][11]. - Net debt was reduced by $1.2 million in the fourth quarter, improving the leverage ratio to 1.09, the lowest level in nine years[3][15]. - Net cash provided by operating activities decreased to $37,176,000 in 2025 from $56,388,000 in 2024, a decline of 34.0%[39]. - Free cash flow for the year ended December 31, 2025, was $25,967,000, compared to $37,176,000 in operating cash flow after capital expenditures of $11,209,000[54]. - The company repaid $63,000,000 in long-term debt during 2025, compared to $82,000,000 in 2024, indicating a reduction in debt repayment[39]. - Long-term debt, net, decreased to $110,255,000 as of December 31, 2025, down 3.4% from $114,103,000 in Q3 2025[37]. - The cash and cash equivalents at the end of 2025 were $22,847,000, an increase from $19,157,000 at the end of 2024[39]. Segment Performance - Reservoir Description segment revenue for Q4 2025 was $92.3 million, up 5% sequentially and over 6% year-over-year, with operating margins of 14%[5]. - Production Enhancement segment revenue for Q4 2025 was $46.0 million, up over 8% year-over-year, with operating margins, ex-items, of 7%[8]. - The company anticipates first quarter 2026 revenue for Reservoir Description to range from $82 million to $86 million[25]. Future Guidance - First quarter 2026 revenue is projected to range from $124 million to $130 million, with EPS expected to be $0.11 to $0.15[26]. - The Company’s first quarter 2026 guidance includes an effective tax rate of 25% and reflects a higher interest rate due to a term loan of $50,000,000[27]. Tax and Capital Expenditures - The effective tax rate for Q4 2025 was 45%, significantly higher than 21% in Q3 2025 and 35% in Q4 2024[33]. - Capital expenditures for operations in 2025 totaled $11,209,000, slightly down from $11,888,000 in 2024[39]. Return on Investment - The return on invested capital (ROIC) was reported at 9.7%, calculated from a net operating profit after tax (NOPAT) of $38.8 million against an average total invested capital of $398.5 million[51]. Acquisitions - Core Lab completed the acquisition of Brazilian-based Solintec for approximately $2.3 million[13].

Group 1 - The article discusses the importance of enabling Javascript and cookies in browsers to prevent access issues [1] - It highlights that users with ad-blockers may face restrictions when trying to access content [1]

Group 1 - The article discusses the weekly sector and stock rankings provided by Limelight Alpha Management Partners, which utilizes a quantitative ranking system that combines fundamental, technical, and seasonal data to evaluate sectors and industries [1] - Limelight Alpha Management Partners ranks over 1,600 institutional quality stocks weekly, identifying the best and worst performing stocks across various market capitalizations, including ADR, large cap, mid cap, and small cap [1] - The investing group "Top Stocks for Tomorrow" offers systematic idea generation based on market cap, sector, industry, and individual stocks, along with reports on the best stocks by sector and best dividend stocks [1]

Core Insights - Core Laboratories Inc. (CLB) is expected to report fourth-quarter 2025 results on February 4, with a consensus estimate of earnings at 20 cents per share and revenues at $132 million [1][7]. Q3 Earnings Highlights - In the last reported quarter, CLB's adjusted earnings were 22 cents per share, exceeding the consensus estimate by 3 cents, while operating revenues reached $134.5 million, surpassing the estimate of $128 million due to increased demand for laboratory analytical and completion diagnostic services internationally [2]. Earnings Surprise History - CLB has missed the Zacks Consensus Estimate in two of the last four quarters and beat it in the other two, resulting in an average surprise of 2.58% [3]. - The consensus estimate for fourth-quarter 2025 earnings has remained unchanged over the past 30 days, indicating a year-over-year decline of 9.09%, while revenue estimates show a 2.35% increase compared to the previous year [3]. Factors Influencing Q4 Performance - CLB's revenue is anticipated to improve due to strong performance in both the Reservoir Description and Production Enhancement segments [4]. - However, rising costs are expected to impact the bottom line, with total operating expenses projected at $117.7 million, a 2.3% increase from the previous quarter, and costs of services and product sales expected to reach $108.4 million, up 2% from last quarter [5]. Earnings Prediction Model - The Zacks model does not predict an earnings beat for CLB this quarter, as the Earnings ESP is 0.00% and the company holds a Zacks Rank of 3 (Hold) [6][8].

Core Viewpoint - Investors are evaluating Halliburton (HAL) and Core Laboratories (CLB) for potential undervalued stock opportunities in the Oil and Gas - Field Services sector [1] Group 1: Company Rankings - Halliburton has a Zacks Rank of 2 (Buy), while Core Laboratories has a Zacks Rank of 3 (Hold), indicating a stronger earnings outlook for HAL [3] Group 2: Valuation Metrics - HAL has a forward P/E ratio of 15.14, significantly lower than CLB's forward P/E of 24.61, suggesting HAL may be undervalued [5] - The PEG ratio for HAL is 2.04, compared to CLB's PEG ratio of 16.86, indicating HAL's expected earnings growth is more favorable [5] - HAL's P/B ratio is 2.74, while CLB's P/B ratio is 3.24, further supporting HAL's valuation advantage [6] Group 3: Value Grades - Based on various valuation metrics, HAL holds a Value grade of B, whereas CLB has a Value grade of C, making HAL the more attractive option for value investors [6]

Core Insights - Core Laboratories Inc. (CLB) has demonstrated exceptional growth over the past six months, with a share price increase of 48.2%, significantly outperforming the Oil & Gas Field Services sub-industry's growth of 25.1% and the broader Oil and Energy sector's increase of 7.1% [1][8] Financial Performance - In the third quarter of 2025, CLB reported revenues of $134.5 million, reflecting a sequential growth of over 3% [5][8] - The company achieved notable improvements in operating income, operating margins (ex-items), and earnings per share, indicating effective cost management and positive business momentum [5][8] Market Position - Approximately 80% of CLB's Reservoir Description revenues are derived from international and offshore projects, which are less sensitive to short-term commodity price fluctuations [6][9] - The company holds a leading market position in providing essential rock and fluid analysis, creating a stable, high-margin revenue base [9][18] Technological Edge - CLB's proprietary technologies have been instrumental in solving critical client problems, showcasing its technical differentiation and role as a high-value partner [10][18] International Growth Opportunities - Management reports increased planned activity from clients globally, particularly in the Middle East, South Atlantic Margin, and West Africa, with new momentum in the Asia Pacific [11][18] Challenges and Risks - Product sales decreased by 6% year over year in Q3 2025, and rising costs for imported steel due to tariffs have pressured margins [12] - The company faces concentration risk in international markets, exposing it to regional economic, political, and currency risks [13] - CLB's P/E ratio of 21.41 is significantly higher than the sub-industry average of 17.93, raising valuation concerns [14] - Integration challenges from the recent acquisition of Solintec could divert management attention and incur unexpected costs [15]

Core Laboratories Overview - Core Laboratories (CLB) is an engineering and diagnostic service provider to the global oil and gas industry, offering technical and field support services to characterize well geological and production [1] Investment Insights - The firm is positioned to aid in evaluating potential equities worthy of long-term investment, focusing on income-producing equities and rental real estate properties for cash flow and long-term appreciation [1]

Core Insights - Core Laboratories Inc. (CLB) generates revenues by providing specialized services and products to the oil and gas industry, focusing on reservoir optimization, production enhancement, and geological analysis [1] - The company’s primary revenue streams include laboratory services, equipment sales, and data analytics, which assist clients in maximizing productivity and efficiency in exploration and production operations [1] Performance Overview - Over the past three months, CLB's share price increased by 33.9%, outperforming the broader Oil & Energy Market, which gained only 2.7% [3][4] - Compared to competitors, TechnipFMC plc (FTI) and Halliburton (HAL) saw gains of 20.7% and 18.6%, respectively, while KLX Energy (KLXE) experienced a decline of 26.1% [3] Earnings Estimates - The Zacks Consensus Estimate for CLB's earnings per share has remained unchanged for the first and second quarters, while estimates for the next fiscal year (F1) increased by 4.17% [8] Key Drivers of Stock Momentum - CLB's services align with long-term industry investment trends, as significant annual investment in oil and gas resource development is necessary to offset declining rates in existing fields [10] - The strategic acquisition of Solintec in Brazil enhances Core Lab's capabilities and includes an earn-out structure that ties part of the purchase price to future performance [11] - The company reported a return on invested capital (ROIC) of 9.7% for the third quarter of 2025, indicating efficient capital deployment [12] - CLB is focused on high-value, long-cycle international projects, providing a stable revenue stream less sensitive to commodity price fluctuations [13] - Management believes that proposed tariff measures would not impact more than 75% of the company's revenues, providing insulation against trade policy disruptions [14] Challenges and Risks - For the third quarter of 2025, revenues were essentially flat at $134.5 million, indicating a mature, low-growth environment [17] - The company is vulnerable to geopolitical and macroeconomic volatility, particularly in regions like the Middle East and Latin America [18] - Growth assumptions are based on optimistic projections from industry organizations, which may not materialize [19] - The U.S. onshore market is experiencing a seasonal decline, with product sales down 6% year over year in the third quarter of 2025 [20] - Core Lab's exposure to the cyclical nature of the oil and gas service sector mirrors that of its competitors, making it susceptible to reduced demand during low commodity price periods [21] Final Analysis - CLB benefits from alignment with long-term industry trends, a successful acquisition, and strong ROIC, enhancing its investment case [22] - However, challenges include modest revenue growth, geopolitical vulnerabilities, and reliance on optimistic energy demand projections [23]

Core Laboratories Inc. Overview - Core Laboratories Inc. (NYSE:CLB) is currently trading at $14.95, reflecting a 0.60% decrease in the session. Over the past month, the stock has decreased by 6.33%, and over the past year, it has declined by 26.54% [1]. Price-to-Earnings (P/E) Ratio Analysis - The P/E ratio is a critical metric for long-term investors, measuring the current share price against the company's earnings per share (EPS). A higher P/E ratio suggests that investors expect better future performance, which may indicate overvaluation or optimism about future dividends [5]. - Core Laboratories has a P/E ratio of 22.12, which is higher than the aggregate P/E ratio of 21.78 for the Energy Equipment & Services industry. This may imply that Core Laboratories is expected to perform better than its industry peers, although it could also indicate that the stock is overvalued [6]. Caution in P/E Ratio Interpretation - While the P/E ratio is a valuable tool for evaluating market performance, it should be used cautiously. A low P/E ratio may indicate undervaluation but could also suggest weak growth prospects or financial instability. It is essential to consider the P/E ratio alongside other financial metrics, industry trends, and qualitative factors for a comprehensive analysis [9][10].